Century Therapeutics, Inc. (IPSC)

NASDAQ: IPSC · IEX Real-Time Price · USD
4.84
+0.20 (4.31%)
At close: Feb 3, 2023, 4:00 PM
4.60
-0.24 (-4.96%)
After-hours: Feb 3, 2023, 7:50 PM EST
4.31%
Market Cap 285.44M
Revenue (ttm) 4.68M
Net Income (ttm) -127.44M
Shares Out 58.97M
EPS (ttm) -1.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 238,660
Open 4.61
Previous Close 4.64
Day's Range 4.58 - 5.00
52-Week Range 4.34 - 15.38
Beta n/a
Analysts Buy
Price Target 20.09 (+315.08%)
Earnings Date Mar 16, 2023

About IPSC

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 170
Stock Exchange NASDAQ
Ticker Symbol IPSC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for IPSC stock is "Buy." The 12-month stock price forecast is $20.09, which is an increase of 315.08% from the latest price.

Price Target
$20.09
(315.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...

4 days ago - GlobeNewsWire

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.

Other symbols: EDITELEVFATEJNJYMAB
1 week ago - MarketBeat

5 Health Care Stocks That Are Diving - And May Rally

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: FATENVOSSNPXTECH
2 weeks ago - Benzinga

After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC)

Century Therapeutics, Inc. (IPSC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana...

2 weeks ago - Zacks Investment Research

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: FATEGRPHTHRDVERA
3 weeks ago - Benzinga

Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head

Century Therapeutics is closing its Seattle operations as part of a 25% reduction in headcount and a shift in its priorities.

3 weeks ago - GeekWire

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC

Layoffs have been making headlines so far in 2023, even though we're just a few days into the new year. That's true even for gene-editing stocks.

Other symbols: FATETCRR
1 month ago - InvestorPlace

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

- Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma -

1 month ago - GlobeNewsWire

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...

1 month ago - GlobeNewsWire

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...

2 months ago - GlobeNewsWire

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

- Preclinical data support next generation platform for iPSC-derived NK cells with multiple gene edits to improve persistence and anti-tumor efficacy -

3 months ago - GlobeNewsWire

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 10.17% and 42.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

3 months ago - Zacks Investment Research

Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies expected to begin imminently -

3 months ago - GlobeNewsWire

Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022

PHILADELPHIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics  (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...

3 months ago - GlobeNewsWire

Century Therapeutics to Present at the SITC 37th Annual Meeting

PHILADELPHIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics  (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...

4 months ago - GlobeNewsWire

Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors

PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...

4 months ago - GlobeNewsWire

Century Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...

4 months ago - GlobeNewsWire

Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...

5 months ago - GlobeNewsWire

Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection

– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA –

5 months ago - GlobeNewsWire

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of -8% and 16.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma is on track to commence in the second half o...

6 months ago - GlobeNewsWire

Century Therapeutics Announces Its Addition to the Russell Microcap® Index

PHILADELPHIA, June 24, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...

8 months ago - GlobeNewsWire

Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

PHILADELPHIA, June 21, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...

8 months ago - GlobeNewsWire

Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022

PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...

8 months ago - GlobeNewsWire

Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence in the second half of 2022 following IND submission in mid 2022-

9 months ago - GlobeNewsWire